The calcium modulators have been a significant therapeutic advancement for the treatment of angina. Structural analogs of verapamil and nifedipine have been synthesized, as have structurally unique compounds. As the role of calcium in body processes is further elucidated, the efficacy of the calcium modulators is being evaluated for numerous disorders. It is anticipated that the newly synthesized compounds will have specificity toward particular body processes, thus providing efficacy with minimal side effects.
FleckensteinA.Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the production and prevention of myocardial lesions. In: HarrisPOpieL, eds. Calcium and the heart. Proceedings of the European Section of the International Study Group of Research in Cardiac Metabolism.London: Academic Press, 1970: 135–88.
2.
FleckensteinA.History of calcium antagonists.Circ Res1983; 52(suppl II):1–16.
3.
FleckensteinA.Calcium antagonism in heart and smooth muscle.New York: John Wiley and Sons, 1983.
4.
KatzAMHagerWDMessineoFCPappanoAJ.Cellular actions and pharmacology of the calcium channel blocking drugs.Am J Med1985; 79(suppl 4A):2–10.
5.
SinghBNBakySNademaneeK.Second-generation calcium antagonists: search for greater selectivity and versatility.Am J cardiol1985; 55: 214B–21B.
6.
MoritaTYoshinoKKanazawaTItoKNoseT.Vasodilator action of KB-944, a new calcium antagonist.Arzneimittelforschung1982: 32:1037–42.
7.
RosendorffCGoodmanC.Double-blind double-dummy crossover study of the efficacy and safety of nisoldipine (Bayk5552) versus nifedipine.Curr Ther Res1985; 37: 912–20.
8.
KazdaSGarthoffBKrauseHPSchlobmannK.Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments.Arzneimittelforschung1982; 32: 331–7.
9.
ThuillezCGueretMDuhazePLhosteFKiechelJRGiudicelliJF.Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers.Br J Clin Pharmacol1984; 18: 837–47.
10.
MetzgerHSternHOPfitzerGRueggJC.Calcium antagonists affect calmodulin-dependent contractility of a skinned smooth muscle.Arzneimittelforschung1982; 32: 1425–7.
11.
BostromSLjungBMardhSForsenSThulinE.Interaction of the antihypertensive drug felodipine with calmodulin.Nature1981; 292: 777–8.
12.
ThayerSAFairhurstAS.The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors.Mol Pharmacol1983; 24: 6–9.
13.
ItohHIshikawaTHidakaH.Effects on calmodulin of bepridil, an antianginal agent.J Pharmacol Exp Ther1984; 230: 737–41.
14.
RahwanRGFaustMMWitiakDT.Pharmacological evaluation of new calcium antagonists: 2-substituted 3-dimethylamino-5,6-methylenedioxyindenes.J Pharmacol Exp Ther1977; 201: 126–37.
15.
BurchfieldDMRallJARahwanRG.Effects of 2-n-butyl 3-dimethyl-amino-5,6-methylenedioxyindene on skeletal muscle mechanics and energetics.Am J Physiol1982; 242: C347–52.
16.
RahwanRGGeraldMC.The effect of 2-n-propyl-3-dimethyl-amino-5,6-methylenedioxyindene on caffeine induced contractures of skeletal muscle.Can J Physiol Pharmacol1981; 59: 617–20.
17.
PiascikMFRahwanRGWitiakDT.Pharmacological evaluation of new calcium antagonists: 2-substituted 3-dimethyl-amino-5,6-methylenedioxyindenes. Effects on adrenomedullary catecholamine secretion.J Pharmacol Exp Ther1978; 205: 155–63.
18.
PiascikMFPiascikMTWitiakDTRahwanRG.Pharmacological evaluation of new calcium antagonists: 2-substituted 3-dimethylamino-5,6-methylenedioxyindenes. Antiarrhythmic effects.Can J Physiol Pharmacol1979; 57: 1350–8.
19.
PiascikMFRahwanRGWitiakDT.Pharmacological evaluation of new calcium antagonists: 2-substituted 3-dimethyl-amino-5,6-methylenedioxyindenes. Effects on isolated hearts and coronary vessels.J Pharmacol Exp Ther1979; 210: 141–6.
20.
MassiniPKaser-GlanzmannRLuscherEF.Movement of calcium ions and their role in the activation of platelets.Thromb Haemost1978; 40: 212–7.
21.
MurerEHStewartGJDavenportKSiojoERahwanRGWitiakDT.Effect of three calcium antagonists on platelet secretion and metabolism.Biochem Pharmacol1981; 30: 523–30.
22.
ChiouCYMalagodiMHSastryBVRPosnerP.Effects of calcium antagonist, 6-(N,N-diethylamino)hexyl-3,4,5-trimethoxybenzoate, on digitalis-induced arrhythmias and cardiac contractions.J Pharmacol Exp Ther1976; 198: 444–9.
23.
MalagodiMHChiouCY.Pharmacological evaluation of a new calcium antagonist, 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate hydrochloride (TMB-8): studies in smooth muscles.Eur J Pharmacol1974; 27: 25–33.
24.
MalagodiMHChiouCY.Pharmacological evaluation of a new calcium antagonist, 8-(N,N-diethylamino)octyl-3,4,5-tri-methoxybenzoate hydrochloride (TMB-8): studies in skeletal muscles.Pharmacology1974; 12: 20–31.
Package insert. Cardizem.Kansas City, MO: Marion Laboratories Inc., 1984.
28.
RosenfeldC.Nifedipine in the long-term treatment of hypertensive out-patients.Curr Ther Res1983; 34: 587–94.
29.
VinciMGiglioARaccitiTNifedipine in the long-term treatment of essential arterial hypertension.Curr Ther Res1984; 35: 695–9.
30.
BayleySDobbsRJRobinsonBF.Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.Br J Clin Pharmacol1982; 14: 509–12.
31.
MaedaKTanakaCTsukanoYAntihypertensive effects of the calcium antagonistic agent nifedipine.Arzneimittelforschung1982; 32: 267–71.
32.
MuiesanGAgabiti-RoseiECastellanoMAntihypertensive and humoral effects of verapamil and nifedipine in essential hypertension.J Cardiovasc Pharmacol1982; 4(suppl 3):325–9.
33.
OlivariMTBartorelliCPoleseAFiorentiniCMoruzziPGuazziMD.Treatment of hypertension with nifedipine, a calcium antagonistic agent.Circulation1979; 59: 1056–62.
34.
KiowskiWBertelOErnePHemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine.Hypertension1983; 5(suppl 1):70–4.
35.
Lederballe PedersonOChristensenCKMikkelsenERamschKD.Relationship between the antihypertensive effect and steady state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.Eur J Clin Pharmacol1980; 18: 287–93.
36.
Lederballe PedersonOMikkelsenE.Acute and chronic effects of nifedipine in arterial hypertension.Eur J Clin Pharmacol1978; 14: 375–81.
37.
GiuntoliFGuidiGScalabrinoANifedipine as single drug therapy in hypertension.Curr Ther Res1981; 30: 447–52.
38.
ErnePBolliPBertelOFactors influencing the hypotensive effect of calcium antagonists.Hypertension1983; 5(suppl II):97–102.
39.
MidtboKHalsOVan Der MeerJ.Verapamil compared with nifedipine in the treatment of essential hypertension.J Cardiovasc Pharmacol1982; 4(suppl 3):363–8.
40.
GuazziMDFiorentiniCOlivariMTBartorelliANecchiGPoleseA.Short and long term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension.Circulation1980; 61: 913–9.
41.
AokiKKondOSMochizukiA, Antihypertensive effect of cardiovascular Ca** antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.Am Heart J1978; 96: 218–26.
42.
MurphyMBScrivenAJIDolleryCT.Efficacy of nifedipine as a step 3 antihypertensive drug.Hypertension1983; 5(suppl II):118–21.
43.
BursztynMGrossmannERosenthalT.Long acting nifedipine in the treatment of severe hypertension.Eur J Clin Pharmacol1984; 27: 13–7.
44.
KendallMJDeanS.The use of nifedipine as third line therapy in the treatment of severe hypertension.Postgrad Med J1983; 59(suppl 2): 119–23.
45.
EvansMGOlanoffLSHurwitzGCowartTDConradiEC.Use of nifedipine as an adjunct to current antihypertensive therapy.Arch Intern Med1984; 144: 985–7.
46.
BuhlerFRHulthenULKiowskiWMullerFBBolliP.The place of the calcium antagonist verapamil in antihypertensive therapy.J Cardiovasc Pharmacol1982; 4(suppl 3):350–7.
47.
LewisGRJMorleyKDLewisBMBonesPJ.The treatment of hypertension with verapamil.NZ Med J1978; 87: 351–4.
48.
MidtboKHalSO.Verapamil in the treatment of hypertension.Curr Ther Res1980; 27: 830–8.
49.
GouldBAHornungRSMannS.BalasubramanianVRafteryEB.Slow channel inhibitors verapamil and nifedipine in the management of hypertension.J Cardiovasc Pharmacol1982; 4(suppl 3):369–73.
50.
AnavekarSNChristophidisNLouisWJDoyleAE.Verapamil in the treatment of hypertension.J Cardiovasc Pharmacol1981; 3: 287–92.
51.
LewisGRJ.Verapamil in the management of chronic hypertension.Clin Invest Med1980; 3: 175–7.
52.
HedbackBHermannLS.Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension.Acta Med Scand1984; (suppl 681):129–35.
53.
FrishmanWHKleinNAKleinPComparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris: a placebo-controlled double blind randomized crossover trial.Am J Cardiol1982; 50: 1164–72.
54.
HornungRSJonesRIGouldBASonechaTRafteryEB.Propranolol versus verapamil for the treatment of essential hypertension.Am Heart J1984; 108: 554–60.
55.
LeonettiGPasottiCFerrariGPZanchettiA.Verapamil and propranolol: a comparison of two antihypertensive agents.Acta med Scand1984; (suppl 681):137–41.
56.
LeonettiGCuspidiCSampieriLTerzoliLZanchettiA.Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects.J Cardiovasc Pharmacol1982; 4(suppl 3):319–24.
57.
LearyWPAsmalAC.Treatment of hypertension with verapamil.Curr Ther Res1979; 25: 747–52.
58.
BuhlerFRHulthenULKiowskiWBolliP.Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients.Clin Sci1982; 63: 439s–42s.
59.
Agabiti-RoseiEAlicandriCBeschiMBlood pressure, catecholamines, renin and aldosterone during short and long-term treatment of essential hypertension with verapamil (abstract).Am J Cardiol1982; 49: 912.
60.
InouyeIKMassieBMBenowitzNSimpsonPLogeD.Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide.Am J Cardiol1984; 53: 1588–92.
61.
TrimarcoBDelucaNRicciardelliBDiltiazem in the treatment of mild or moderate essential hypertension. Comparison with metoprolol in a crossover double-blind trial.J Clin Pharmacol1984; 24: 218–27.
62.
KleinWBrandtDVreckoKHarringerM.Role Of calcium antagonists in the treatment of essential hypertension.Circ Res1983; 52(suppl I): 174–81.
63.
AokiKSatoKKondoSYamamotoM.Hypertensive effects of diltiazem to normal and essential hypertensives.Eur J Clin Pharmacol1983; 25: 475–80.
64.
LorimerARElmfeldtDJohnssonGWardA, eds. First international meeting on felodipine.Drugs1984; 29(suppl 2):1–212.
65.
BurtRAPCohenBJBReidJL, eds. Proceedings of the first international symposium on nicardipine.Br J Clin Pharmacol1985; 20(suppl 1):107s–44s.
66.
ParmleyWWSolomonHA.A symposium: future directions in calcium channel blockade with focus on systemic hypertension.Am J Cardiol1986; 58: 1D–40D.
67.
WambachGKaufmannW.Hypotensive Eigenschaften von Nisoldipin.Arzneimittelforschung1984; 34: 620–3.
68.
KusanoEAsanoYTakedaKTeraoNHosodaS.Acute and chronic hypotensive effects of nifedipine and niludipine in hypertensive patients with chronic renal failure.Arzneimittel/orschung1984; 34: 624–9.
69.
AokiKSatoK.Acute hypotensive, hemodynamic effects of long-term treatment with niludipine, a Ca**-antagonist, in patients with essential hypertension.Arzneimittel/orschung1982; 32: 1141–5.
70.
BertelOConenD.RaduEWMullerJLangCDubachUC.Nifedipine in hypertensive emergencies.Br Med J1983; 286: 19–21.
71.
DilmenUCaglarMKSensesDAKinikE.Nifedipine in hypertensive emergencies (letter).Br Med J1983; 286: 889.
72.
ItoHArakawaMShibasakiTAcute antihypertensive effect of nifedipine by sublingual route in cases with clinically severe systolic hypertension.Arzneimittel/orschung1984; 34: 630–6.
73.
HuysmansThMSluiterHEThienTHAKoeneRAP.Acute treatment of hypertensive crisis with nifedipine.Br J Clin Pharmacol1983; 16: 725–7.
74.
MagometschniggDPichlerM.Effective and safe treatment of hypertensive crisis with nifedipine (abstract).Am J Cardiol1981; 47: 469.
75.
GuazziMOlivariMTPoleseAFiorentiniCMagriniFMoruzziP.Nifedipine, a new antihypertensive with rapid action.Clin Pharmacol Ther1977; 22: 528–32.
76.
KuwajimaIUedaKKamataCA study of the effects of nifedipine in hypertensive crisis and severe hypertension.Jpn Heart J1978; 19: 455–67.
77.
TakekoshiNMurakamiEMurakamiHTreatment of severe hypertension and hypertensive emergency with nifedipine, a calcium antagonistic agent.Jpn Circ J1981; 45: 852–60.
78.
PoleseAFiorentiniCOlivariMTGuazziMD.Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema.Am J Med1979; 66: 825–30.
79.
ConenDBertelODubachUC.An oral calcium antagonist for treatment of hypertensive emergencies.J Cardiovasc Pharmacol1982; 4(suppl 3):378–82.
80.
ErbelRBrandGMeyerJEffertS.Emergency treatment of hypertensive crisis with sublingual nifedipine.Postgrad Med J1983; 59(suppl 3):134–6.
81.
LaccheABasagliaP.Hypertensive emergencies: effects of therapy by nifedipine administered sublingually.Curr Ther Res1983; 34: 879–87.
82.
BeerNGallegosICohenAKleinNSonnenblickEFrishmanW.Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.Chest1981; 79: 571–4.
83.
BenderF.Die Behandlung der Tachycarden Arrhythmien und der arteriellen Hypertonie mit Verapamil (English abstract).Arzneimittel/orschung1970; 20(suppl):1310–6.
BrittingerDWSchwarzbeckAWittenmeirKW.Klinish experimentelle Untersuchungen über die bluntdrucksendende Wrikung von Verapamil (English abstract).Dtsch Med Wochenschr1970; 95: 1871–7.
86.
FrishmanWHWeinbergPPeledHBKimmelBCharlapSBeerN.Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis.Am J Med1984; 77(2B):35–45.
87.
RubinLJNicodPHillisLDFirthBG.Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation.Ann Intern Med1983; 99: 433–8.
88.
OlivariMTCohnJNCarlylePLevineTB.Beneficial hemodynamic and exercise response to nifedipine in pulmonary hypertension (abstract).JACC1983; 1: 735.
89.
McleodAAWiseJRDalyKJewittDE.Nifedipine in primary and secondary pulmonary hypertension (abstract).Circulation1981; 64(suppl IV):IV–180.
90.
FisherJBorerJSMosesJWPulmonary hypertension: comparative effects of nifedipine vs hydralazine (abstract).Circulation1982; 66(suppl II):II-49.
91.
LandmarkKRefsumAMSimonsenSStorsteinO.Verapamil and pulmonary hypertension.Acta Med Scand1978; 204: 299–302.
HungJ-SYehS-JLinF-CFuMLeeY-SWuD.Usefulness of intravenous diltiazem in predicting subsequent electrophysiologic and clinical responses to oral diltiazem.Am J Cardiol1984; 54: 1259–62.
94.
GmeinerRNgCKGstottnerM.Effect on paroxysmal re-entrant supraventricular tachycardia of a drug affecting calcium transport (Ro 11–1781).Eur J Clin Pharmacol1979; 16: 155–64.
95.
SungRJElserBMcallisterRG.Intravenous verapamil for termination of reentrant supraventricular tachycardias. Intracardiac studies correlated with plasma verapamil concentrations.Ann Intern Med1980; 93: 682–9.
96.
HengMKSinghBNRocheAHG, Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram.Am Heart J1975; 90: 487–98.
97.
MasonJWSwerdlowCDMitchellLB.Efficacy of verapamil in chronic, recurrent ventricular tachycardia.Am J Cardiol1983; 51: 1614–7.
98.
LevineJHMichaelJRGuarnieriT.Treatment of multifocal atrial tachycardia with verapamil.N Engl J Med1985; 312: 21–5.
99.
RosingDRIdanpaan-HeikkilaUMaronBJBonowROEpsteinSE.Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy.Am J Cardiol1985; 55: 185B–95B.
100.
ClarkREMagovernGJChristliebIYBoeS.Nifedipine cardioplegia experience: results of a 3-year cooperative clinical study.Ann Thorac Surg1983; 36: 654–63.
101.
MossAJ.Current status of calcium channel blocking drugs after myocardial infarction.Eur Heart J1986; 7(suppl A):31–4.
102.
GibsonRSBodenWETherouxPDiltiazem and reinfarction in patients with non-q-wave myocardial infarction.N Engl J Med1986; 315: 423–9.
103.
McgoonMDVlietstraREHolmesDROsbornJE.The clinical use of verapamil.Mayo Clin Proc1982; 57: 495–510.
104.
SolomonGDSteelJGSpaccaventoLJ.Verapamil prophylaxis of migraine.JAMA1983; 250: 2500–2.
105.
MarkleyHGCheronisJCDPiephoRW.Verapamil in prophylactic therapy of migraine.Neurology1984; 34: 973–6.
106.
MeyerJSDowellRWalkerM.Calcium antagonists are effective in prophylactic treatment of all types of vascular headache.Ann Neurol1984; 16: 113–4.
107.
MarkleyHGWorcesterMACheronisJCD.Treatment of acute migraine with intravenous verapamil (abstract).Neurology1984; 34(suppl 1):245.
108.
KahanAWeberSAmorBGuerinFDegeorgesM.Nifedipine in the treatment of migraine in patients with Raynaud's phenomenon (letter).N Engl J Med1983; 308: 1102–3.
109.
MeyerJSHardenbergJ.Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches.Headache1983; 23: 266–77.
GelmersHJ.Nimodipine, a new calcium antagonist, in the pro-phylactic treatment of migraine.Headache1983; 23: 106–9.
112.
DiamondSSchenbaumH.Flunarizine, a calcium channel blocker in the prophylactic treatment of migraine.Headache1983; 23: 39–42.
113.
LouisP.A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine.Headache1981; 21: 235–9.
114.
BoniverR.Vertigo, particularly of vascular origin, treated with flunarizine (R14950).Arzneimittelforschung1978; 28: 1800–4.
115.
HofferberthB.Die Anwendung von Flunarizin bei Patienten mit vertebrobasilärer Insuffizienz.Arzneimittelforschung1980; 30: 1817–9.
116.
DoranARNarangPKMeigsCYVerapamil concentrations in cerebrospinal fluid after oral administration (letter).N Engl J Med1985; 312: 1261–2.
117.
MeyerFBAndersonRESundtTMSharbroughFW.Selective central nervous system calcium channel blockers—a new class of anticonvulsant agents.Mayo Clin Proc1986; 61: 239–47.
118.
AllenGSAhnHSPreziosiTJ.Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage.N Engl J Med1983; 308: 619–24.
119.
GelmersHJ.The effects of nimodipine on the clinical course of patients with acute ischemic stroke.Acta Neurol Scand1984; 69: 232–9.
120.
McleanMJGebarskiSSVan Der SpekAFLGoldsteinGW.Response of moyamoya disease to verapamil (letter).Lancet1985; 1: 163–4.
121.
SmithCDMckendryRJR.Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.Lancet1982; 2: 1299–301.
122.
RodehefferRJRommerJAWigleyFSmithCR.Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.N Engl J Med1983; 308: 880–3.
123.
KinneyELNicholasGGGalloJPontorieroCZelisR.The treatment of severe Raynaud's phenomenon with verapamil.J Clin Pharmacol1982; 22: 74–6.
124.
MatobaTOgataMKuwaharaH.Diltiazem and Raynaud's syndrome (letter).Ann Intern Med1982; 97: 455.
KahanAAmorBMenkesCJ.A randomized double-blind trial of diltiazem in the treatment of Raynaud's phenomenon (abstract).Circulation1983; 68(suppl III):111–263.
127.
SchetzJBostoenHClementDFlunarizine in chronic obstructive peripheral arterial disease: a placebo-controlled, double-blind, randomized multicentre trial.Curr Ther Res1978; 23: 121–30.
128.
WilliamDOBarnesPJVickersHPRudolfM.Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma (letter).Br Med J1981; 283: 348.
129.
BarontiAGriecoMLelliMVibelliCVirgiliG.Reduction of airway hyperresponsiveness in allergic asthmatic and rhinitic patients by acute nifedipine.Curr Ther Res1984; 35: 247–52.
130.
PatelKR.Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma (letter).Br Med J1981; 283: 796.
131.
PatelKR.Calcium antagonists in exercise-induced asthma.Br Med J1981; 282: 932–3.
132.
HillMHendelesLMoorePHarmanEPieperJAPeelerD.The effect of increasing doses of inhaled verapamil on airway reactivity to methacholine in mild asthmatics: a paradoxical response (abstract).Drug Intell Clin Pharm1985; 19: 464–5.
133.
UlmstenUAnderssonKEWingerupL.Treatment of premature labor with the calcium antagonist nifedipine.Arch Gynecol1980; 229: 1–5.
134.
KaulAFOsathanondhRSafonLEFrigolettoFDFriedmanPA.The management of preterm labor with the calcium channel-blocking agent nifedipine combined with the beta-mimetic terbutaline.Drug Intell Clin Pharm1985; 19: 369–71.
135.
TraubeMHongoMMagyarLMccallumRW.Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions.JAMA1984; 252: 1733–6.
136.
BortolottiMLaboG.Clinical and manometric effects of nifedipine in patients with esophageal achalasia.Gastroenterology1981; 80: 39–44.
137.
SamueliFBonabelloAGrassiA.Antagonistic activity of verapamil and diltiazem against different intestinal smooth muscle stimuli.Arzneimittelforschung1984; 34: 181–4.
138.
GoetschRAFinkSChaudhuriTK.Effect of nifedipine on gastric emptying.Milit Med1986; 151: 438–9.
139.
Overcoming drug resistance in the treatment of cancer.Am Pharm1984; NS24:12–4.
140.
SlaterLMMurraySLWetzelMWSweetPStupeckyM.Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.Cancer Chemother Pharmacol1986; 16: 50–4.
141.
TsuruoTIidaHTsukagoshiSSakuraiY.Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.Cancer Treat Rep1985; 69: 523–5.
142.
BensonABTrumpDLKoellerJMPhase I study of vinblastine and verapamil given by concurrent iv infusion.Cancer Treat Rep1985; 69: 795–9.
143.
OnoHKimuraM.Effect of calcium-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.Arzneimittelforschung1981; 31: 1131–4.
144.
RibeiroLGTBrandonTAHorakJKWareJAMillerRRSolisRT.Inhibition of platelet aggregation by verapamil: quantification by in vivo and in vitro techniques.J Cardiovasc Pharmacol1982; 4: 170–3.
145.
YamasawaINoharaYKonnoSProtection of the ischemic myocardium with calcium antagonistic drugs.Arzneimittelforschung1983; 33: 389–96.
146.
CarrolW.Nifedipine and ureteral colic (letter).Ann Intern Med1985; 102: 864.
147.
SerfasDShobackDMLorellBH.Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade (letter).Lancet1983; 2: 711–3.
148.
HongCYChiangBNKuJWeiYHFongJC.Calcium antagonists stimulate sperm motility in ejaculated human semen.Br J Clin Pharmacol1985; 19: 45–9.
